A Pilot Clinical Study to Assess the Safety and Effectiveness of the InterCushion Disc Nucleus Prosthesis in Patients Receiving Discectomy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Disk, Herniated
- Sponsor
- Vertebral Technologies, Inc.
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Decrease in ODI
- Last Updated
- 9 years ago
Overview
Brief Summary
The primary endpoints of the investigation will include assessment of the maintenance of disc height demonstrated by radiographic evidence based on plain radiographs and MRI and relief of pain as measured by Visual Analog Scale (VAS) at six months post-surgery. It is anticipated that outcomes with the InterCushion Disc Nucleus Prosthesis (DNP) will be comparable to or better than the historical published results for discectomy alone.
Detailed Description
All patients will be followed for at least 24 months once enrolled in the study. Clinical evaluations will be conducted before surgery (baseline), intraoperative, 2 week (± 1 week), 6 week (± 1 week), 3 months (± 2 weeks), 6 months (± 1 month), 12 months (± 2 months) and 24 months (± 2 months).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient has signed and dated a study specific informed consent form approved by the reviewing Institutional Review Board or Ethics Committee.
- •Patient is 21 to 60 years of age.
- •Patient is skeletally mature
- •Patient requires a discectomy of one level from L2-S
- •Patient has less than 50% loss of disc height at the affected level.
- •Patient has persistent pain (predominantly leg pain, although some back pain that occurred at the same time as the leg pain and is believed to be associated with the disc herniation will not disqualify the patient from participating in this study) and symptoms despite a minimum of six weeks of non-operative treatment.
- •Patient X-ray, CT or MR evidence of a herniated disc at the affected level.
- •Patient has a minimum leg pain score of 6 cm on a 10 cm (i.e. 60 mm on a 100 mm) point visual analog scale (VAS).
- •Patient has a minimum Oswestry Disability Index score of 40% (based upon a 100% scale).
- •Patient is physically and mentally willing and able to comply with the postoperative scheduled clinical and radiographic evaluations and rehabilitation.
Exclusion Criteria
- •Patient has had any previous surgery at the affected levels.
- •Patient has had any attempt at spinal fusion, at any lumbar levels.
- •Patient has motion of \< 3 degrees on pre-operative lateral flexion/extension radiographs
- •Patient has a BMI
- •Patient has severe osteoporosis of the spine.
- •Patient has previously undergone chemotherapy, immunosuppressive therapy or radiation to the local area.
- •Patient has active local or systemic infection.
- •Patient has any known active malignancy.
- •Patient has rheumatoid arthritis or systemic lupus erythematosus, or other chronic, inflammatory autoimmune disorder.
- •Patient has ankylosing spondylitis or other spondyloarthropathy.
Outcomes
Primary Outcomes
Decrease in ODI
Time Frame: 6 months
Improvement in the Oswestry Disability Index (ODI) score i.e. decrease of 15% or better ODI.
Decrease in VAS
Time Frame: 6 months
Improvement in leg pain evidenced by decrease in pain score of at least 2 cm (i.e. 20 mm) on the visual analog scale (VAS)
Maintenance of post-operative disc height
Time Frame: 6 months
Disc at the treated level is collapsed by ≤ 15% when compared to an adjacent health level.
Mobility of treated segment
Time Frame: 6 months
Motion of ≥ 3 degrees on lateral flexion/extension radiographs
Neurologic deficits
Time Frame: 6 months
No new permanent neurological deficit or worsening of an existing permanent neurological deficit
Secondary Outcomes
- Neurological deficits(12 and 24 months)
- Maintenance or decrease in ODI(12 and 24 months)
- Maintenance or decrease in VAS(12 and 24 months)
- Maintenance of post-operative disc height.(12 and 24 months)
- Mobility of treated segment(12 and 24 months)